Les Laboratoires Servier SAS has added to a string of incremental wins for the drug Tibsovo (ivosidenib) since the company bought the rights from Agios Pharmaceuticals, Inc. near the end of 2020, with new positive topline Phase III results in acute myeloid leukemia (AML), though it will be entering a field with steep competition.
Paris-based Servier said 2 August that topline results of AGILE showed that Tibsovo combined with Bristol Myers Squibb Company’s Vidaza (azacitidine) improved event-free survival (EFS), the trial’s primary endpoint, as well as producing improvements on key secondary endpoints like complete remission (CR) rate, objective response rate (ORR) and overall survival (OS)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?